Skip to main content
Industry News
FDA accepts application filed by Apellis for PNH drug

Apellis Pharmaceuticals announced that its marketing application for pegcetacoplan, which is under priority review status, has been accepted by the FDA, with an action date set for May 14. Pegcetacoplan was developed to treat the rare blood disorder paroxysmal nocturnal hemoglobinuria.

Full Story: